TRISHA ESTES: Open Payments
NPI 1811586522 · PAPILLION, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$789 in 43 payments from 18 companies in 2025. Trend: 2023 $1,235 · 2024 $1,366 · 2025 $789
Food & beverage: $789
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $248 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Astellas Pharma US Inc | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| SANOFI-AVENTIS U.S. LLC | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Lilly USA, LLC | 2 | $34 |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $33 |
| Axsome Therapeutics, Inc. | 2 | $33 |
Products named: UBRELVY, QULIPTA, REXULTI, VRAYLAR, Veozah, HETLIOZ, TZIELD, CAPLYTA.
Industry payments across NE — which companies pay providers there.
